In this interview we talk through the current state of the global response to COVID-19, but we will also talk about what happens next, both in the short-term and the long-term.

Our guest:

Dr. Rohit Ramchandani (BSc ’04) is Founder & CEO at Antara Global Health Advisors, a global consultancy that provides technical expertise & evidence-based public health & management advise to public and private organizations around the world. He is an Adjunct Assistant Professor in the School of Public Health & Health Systems at the University of Waterloo, where he teaches Global Health Innovation, and was recently made a Fellow of the Balsillie School of International Affairs. As Public Health Advisor & Principal Investigator at ColaLife, he has worked around the world to help curb epidemics of diarrheal disease, the second leading cause of death in children under 5 globally. He sits on the Board of Directors of the Jane Goodall Institute of Canada, working on conservation, sustainable development and awareness initiatives at the intersections of animals, people and the environment. Dr. Ramchandani is also co-Chair of the University of Waterloo’s Toronto Alumni Chapter, out largest global alumni chapter, with over 50,000 alumni. In addition to his BSc in Health Studies & Gerontology from the University of Waterloo, he holds a Doctor of Public Health (DrPH) from the Johns Hopkins Bloomberg School of Public Health and a Masters of Public Health (MPH) in Global Health & Epidemiology from Boston University.

In relation to the COVID-19 response, and in collaboration with stakeholders like the World Health Organization, Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Novartis and others, Dr. Ramchandani is currently leading a study and advising an international consortium of donors, on the R&D systems in place for the development of global health products. This includes a review of the R&D processes around diagnostics, therapeutics and vaccines for poverty-related and neglected diseases, including COVID-19. His team is also in the process of developing a platform for tracking the unprecedented innovation arising from the current pandemic

свернуть